Cancer Epidemiology Prevention And Control Program

The Cancer Epidemiology, Prevention and Control (CEPC) program includes collaborative, multi-institutional research that addresses the entire cancer continuum, including the prevention, screening, diagnosis, treatment and long-term outcomes of cancer. The program is jointly supported by the Henry Ford Cancer Institute, the Department of Public Health Sciences, and the Center for Health Services Research. Research emphases include a focus on population sciences including epidemiology, health services, health promotion, health economics, and cancer control.

Research programs

  • Cancer Research Network (CRN): The CRN is a National Cancer Institute funded research network that supports the collaborative efforts of currently 15 health systems across the US and represents collectively the experience of almost 11 million Americans. Research stemming from the CRN encompasses the entire spectrum of cancer prevention and care.
  • Sentinel and OMOP: The Food and Drug Administration is supporting the unique databases of Henry Ford Health System to track medication side effects and outcomes.
  • Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial and the National Lung Screening Trial: CEPC is the Henry Ford Health System seat of these multi-center national trials. Of the 10 PLCO trial sites, we have recruited the second largest number of subjects with over 24,600 individuals. We have also recruited 3,000 current or former smokers for the NLST. Our investigators are active in steering committee and disease group activities. In addition, HFHS leads the Methods and Operations Workgroup for the entire trial.
  • Multi-site HMO Cancer Research Network NCI study of statins and lymphoma
  • Study of the association of NSAIDs and polyps and epidemiological patterns of CA125 in the PLCO study population
  • HMO Cancer Research Network behavioral intervention trial "Making Effective Nutritional Choices"
  • Relationship of NSAID and HRT use and survival among colon cancer patients
  • Cancer risk reduction through lifestyle and behavioral changes
  • Web-based educational interventions to improve detection of skin cancer and communicating genetic risk to patients
  • Racial differences in cardiovascular disease outcomes among men diagnosed with prostate cancer and treated with androgen deprivation therapy
  • Pharmacologic exposures that may increase or decrease cancer risk and the molecular pathways that drugs of interest may influence
  • Developing of algorithms for identification of breast cancer recurrence using automated data
  • Expanding the utility of using existing administrative data sources as a research data laboratory
  • Mapping genes that underlie an individual's susceptibility to cancer, with the hope of ultimately utilizing this information for cancer prevention or early detection of disease
  • Race disparities in the incidence and mortality of prostate and lung cancers with respect to the effects of the built and social environments and lead exposure
  • Molecular and genetic epidemiology of prostate cancer and sarcoidosis
  • Racial and ethnic disparities in quality of care, and on the ways in which health care organizations can reduce or eliminate disparities
  • Racial disparities in the treatment of early stage lung cancer
  • Studying ways to improve the decision making process in which African American patients engage with their physicians to arrive at plans for the adjuvant therapy of lung, breast, and colorectal cancer
  • Screening for lung, prostate, colorectal, and ovarian cancers
  • Reducing delay and barriers to receipt of recommended medical care, social determinants of health outcomes, and medical informatics enhancements in contained health systems to improve disease surveillance
  • Skin cancer outcomes including non-melanoma skin cancer as well as primary care competency in skin cancer screening
  • Molecular mechanisms of breast cancer metastasis, with additional interests in the role of lymphatic invasion as a mechanism to promote regional lymph node metastasis in breast cancer
  • Alternative approaches including acupuncture, exercise and vitamin supplements to improve quality of life of cancer patients

See member profiles for comprehensive cancer research interests

Leader and clinical co-leader

  • Rybicki, Ben, Ph.D.
  • Eide, Melody, M.D.

Research members

  • Alexander, Gwen, Ph.D.
  • Cassidy-Bushrow, Andrea, Ph.D.
  • Divine, George, Ph.D.
  • Flynn, Michael, Ph.D.
  • Hensley-Alford, Sharon, Ph.D.
  • Johnson, Christine Cole, Ph.D.
  • Lamerato, Lois, Ph.D.
  • Levin, Al, Ph.D.
  • Lu, Mei, Ph.D.
  • Neslund Dudas, Christine, Ph.D.
  • Poisson, Laila, Ph.D.

Clinical members

  • Chapman, Robert, M.D.
  • Nathanson, David, M.D.
  • Rogers, Craig, M.D.
  • Walker, Eleanor, M.D.